AOB Pharma and Maruho enter into an agreement for AOB’s B244 for treatment of atopic dermatitis in Japan

The deal includes upfront payments, milestone payments and ongoing royalties

Merck announces Phase 3 trial initiations for 4 Investigational Candidates from hematology and oncology pipeline

Comprehensive clinical development programs being initiated for each investigational candidate

Jiangsu Vcare files NDA for Vicagrel Capsules with USFDA

CCRAS launches ‘SMART 2.0’ for ayurveda teaching professionals

Medway Hospitals raises US$5 million in a financing round led by Kyra Ventures

Medway setup a state-of-the-art Heart Institute in Chennai

Glenmark to launch biosimilar of anti-diabetic drug Liraglutide in India

Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs

WuXi XDC partners with IntoCell to accelerate ADC discovery and development

IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate

Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases

Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes

Cell and gene therapy will be top industry trend for pharma in 2024, finds GlobalData

The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year

Palatin completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn

Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)